Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-142886, MEK inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-142886 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-142886, MEK inhibitor; oral | DRUG | Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule |
Key Inclusion Criteria (Part 2): * Histopathologically or cytologically confirmed solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for which the Investigator feels no other active therapy is required for the duration of the study. * Eastern Cooperat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARRY-142886 is an investigational small molecule MEK inhibitor being studied for the treatment of advanced cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated in patients with advanced cancer to assess its safety and potential efficacy.
ARRY-142886 targets MEK, a protein kinase involved in cell signaling pathways that regulate cell growth and proliferation. By inhibiting MEK, the drug aims to disrupt cancer cell growth. This mechanism is being explored in the treatment of advanced cancer.
ARRY-142886 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials for advanced cancer.
ARRY-142886 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 trial has been completed, and the drug remains under investigation for the treatment of advanced cancer.
ARRY-142886 has one completed Phase 1 clinical trial, identified as NCT00085787, titled "A Study of ARRY-142886 in Patients With Advanced Cancer." The trial enrolled 57 participants in the United States and was an uncontrolled, open-label study.